The intercellular cell adhesion molecule-1 (icam-1) in lung cancer: implications for disease progression and prognosis
EA Kotteas, P Boulas, I Gkiozos, S Tsagkouli… - Anticancer …, 2014 - ar.iiarjournals.org
The intercellular cell-adhesion molecule-1 (ICAM-1) is a transmembrane molecule and a
distinguished member of the Immunoglobulin superfamily of proteins that participates in many …
distinguished member of the Immunoglobulin superfamily of proteins that participates in many …
[HTML][HTML] CD24: a novel target for cancer immunotherapy
…, NK Syrigos, A Charpidou, E Kotteas… - Journal of Personalized …, 2022 - mdpi.com
Cluster of differentiation 24 (CD24) is a small, highly glycosylated cell adhesion protein that
is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor …
is normally expressed by immune as well as epithelial, neural, and muscle cells. Tumor …
Management and outcomes in metaplastic breast cancer
IG Tzanninis, EA Kotteas, I Ntanasis-Stathopoulos… - Clinical breast …, 2016 - Elsevier
Metaplastic breast cancer (MBC) constitutes a rare clinical entity with special clinicopathologic,
immunohistochemical, and molecular features. Resistance to systemic therapies, …
immunohistochemical, and molecular features. Resistance to systemic therapies, …
[HTML][HTML] Osimertinib resistance: molecular mechanisms and emerging treatment options
Simple Summary Osimertinib, a third-generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small-…
tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small-…
Immune checkpoint inhibitor-related pneumonitis
Immune checkpoint inhibitors are novel agents that have been proved efficacious in a
variety of cancer types, but they are associated with a unique set of organ-specific, immune-…
variety of cancer types, but they are associated with a unique set of organ-specific, immune-…
[HTML][HTML] Bcl-2 pathway inhibition in solid tumors: a review of clinical trials
…, I Karavolias, I Trontzas, EA Kotteas - Clinical and …, 2023 - Springer
Due to their key role in the pathogenesis of cancer through the regulation of apoptosis, the B-cell
leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer …
leukemia/lymphoma-2 (BCL-2) family proteins have been an attractive target for cancer …
[HTML][HTML] Tumor dormancy: implications for invasion and metastasis
Tumor dormancy refers to a critical stage of cancer development when tumor cells are present,
but cancer does not progress. It includes both the concept of cellular dormancy, indicating …
but cancer does not progress. It includes both the concept of cellular dormancy, indicating …
[HTML][HTML] Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology …
…, V Georgoulias, M Chrysanthidis, E Kotteas… - Cancer Immunology …, 2022 - Springer
Background Data on the safety and efficacy of immune checkpoint inhibitors (ICI) in patients
with concurrent autoimmune diseases (AID) are limited. Methods We performed a …
with concurrent autoimmune diseases (AID) are limited. Methods We performed a …
Prospective assessment of clinical risk factors and biomarkers of hypercoagulability for the identification of patients with lung adenocarcinoma at risk for cancer …
Background The aim of this prospective study was to identify the most clinically relevant
hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved …
hypercoagulability biomarkers in lung adenocarcinoma patients for elaboration of an improved …
Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors
Cyclin-dependent kinase (CDK) 4/6 inhibitors have emerged in the treatment of metastatic
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-…
hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-…